Premium Peptider
US$ 23.53
copper peptide ghk-cu clinical study skin Prime Journal March/April 2026 Feature Copper Peptide ghk-cu: Skin Biology
Description
Aside from PP405, which is undergoing a Phase II clinical study, none of these peptides is classified as a medicine [10]
Both compounds independently cause nausea, vomiting, diarrhea, and constipation - especially during dose increases
With GLP-1 agonists, the appetite suppression often creates a naturally large deficit without conscious effort
Storage Store according to the batch documentation and handling notes supplied with the product Storage notes are presented as handling context, not as personal-use guidance
